(Q33357201)

26 July 2017

Phase II trial of irinotecan (CPT-11) in relapsed or refractory non-Hodgkin's lymphomas (English)

1 reference

26 July 2017

Phase II Trial of Irinotecan (CPT-11) in Relapsed or Refractory Non-Hodgki n's Lymphomas (English)

1 reference

https://api.crossref.org/works/10.3109/10428190309178775

22 March 2024

main subject

phase II clinical trial

0 references

1 reference

1 reference

https://api.crossref.org/works/10.3109/10428190309178775

22 March 2024

author name string

V. Ribrag

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14565655

22 March 2024

S. Koscielny

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14565655

22 March 2024

J. M. Vantelon

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14565655

22 March 2024

C. Fermé

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14565655

22 March 2024

K. Rideller

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14565655

22 March 2024

P. Carde

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14565655

22 March 2024

J. H. Bourhis

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14565655

22 March 2024

J. N. Munck

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14565655

22 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14565655

22 March 2024

publication date

1 September 2003

1 reference

full work available at URL

26 July 2017

http://www.tandfonline.com/doi/pdf/10.3109/10428190309178775

1 reference

https://api.crossref.org/works/10.3109/10428190309178775

22 March 2024

1 reference

26 July 2017

44

1 reference

26 July 2017

9

1 reference

26 July 2017

1529-1533

1 reference

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

26 July 2017

2

1 reference

https://api.crossref.org/works/10.3109/10428190309178775

Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea

22 March 2024

5

1 reference

https://api.crossref.org/works/10.3109/10428190309178775

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

22 March 2024

6

1 reference

https://api.crossref.org/works/10.3109/10428190309178775

An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma.

22 March 2024

7

1 reference

https://api.crossref.org/works/10.3109/10428190309178775

Irinotecan hydrochloride for the treatment of recurrent and refractory non-Hodgkin lymphoma: a single institution experience

22 March 2024

8

1 reference

https://api.crossref.org/works/10.3109/10428190309178775

Phase I and pharmacokinetic trial of weekly CPT-11

22 March 2024

10

1 reference

https://api.crossref.org/works/10.3109/10428190309178775

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients

22 March 2024

11

1 reference

https://api.crossref.org/works/10.3109/10428190309178775

22 March 2024

Identifiers

10.1080/1042819031000099643

1 reference

26 July 2017

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14565655

22 March 2024

1 reference